This week's People on the Move column features new appointments in the US Food and Drug Administration, Mylan, Biocon and elsewhere.
The FDA’s Office of Manufacturing and Product Quality (OMPQ), located within the Center for Drug Evaluation and Research, has announced the departure of its director Steve Lynn, who will take up a position as VP of global quality and compliance at Mylan after May 9.
During his time with the FDA, Lynn oversaw implementation of the Generic Drug User Fee Act and helped lead compliance projects, including the Ranbaxy and Ben Venue Labs consent decrees.
Lynn will be replaced by Tom Cosgrove, who will serve as acting director of OMPQ. Cosgrove is currently director of the Office of Unapproved Drugs and Labeling (OUDLC), with responsibility for unapproved and misbranded drugs. He previously worked as a litigator at the FDA’s Office of Chief Counsel and was an attorney at Covington & Burling in Washington, DC.
With Cosgrove’s promotion, Kathy Anderson will step into the vacant role of acting director of OUDLC. She is presently a member of senior management in the division, with experience in compliance issues regarding drug registration, imports, unauthorised marketing and fraudulent drugs.
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...